ARCHIVES

Letter to the Editor: IOM Study Welcome For “Omic” Research

This article is from The Cancer Letter archive.

Vol. 36 No. 39 | October 29, 2010

Download PDF Visit The Full Archive

Related Articles

To Industry for Development, NDA

November 18, 1977

FDA Approves Abraxane And Alimta for NSCLC

October 26, 2012

FDA Approved 88% Of Cancer Applications Since Oncology Office Opened In 2005.

July 3, 2008

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

FDA News< Regulations To Ease For Advertising Drugs On TV, Radio

September 12, 1997

Stereotactic Body Radiotherapy Could Improve Overall Survival

July 29, 2011